Celcuity (NASDAQ:CELC) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

Celcuity (NASDAQ:CELC) had its price objective increased by investment analysts at Jefferies Financial Group from $108.00 to $134.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Jefferies Financial Group’s price objective would indicate a potential upside of 36.05% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. Stifel Nicolaus raised their target price on shares of Celcuity from $68.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Guggenheim started coverage on shares of Celcuity in a research note on Monday, September 22nd. They set a “buy” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, October 8th. Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a report on Sunday, October 26th. Finally, Wolfe Research assumed coverage on Celcuity in a research report on Tuesday, November 18th. They set an “outperform” rating and a $110.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $102.29.

Celcuity Trading Down 2.6%

Shares of NASDAQ CELC opened at $98.49 on Tuesday. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The business has a fifty day simple moving average of $70.74 and a two-hundred day simple moving average of $43.84. The firm has a market cap of $4.56 billion, a PE ratio of -26.84 and a beta of 0.21. Celcuity has a twelve month low of $7.57 and a twelve month high of $103.06.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. Analysts expect that Celcuity will post -2.62 earnings per share for the current fiscal year.

Insider Transactions at Celcuity

In other Celcuity news, Director Richard E. Buller sold 3,900 shares of Celcuity stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $96.73, for a total value of $377,247.00. Following the transaction, the director directly owned 7,260 shares of the company’s stock, valued at approximately $702,259.80. The trade was a 34.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 15.78% of the company’s stock.

Institutional Trading of Celcuity

A number of institutional investors have recently made changes to their positions in the business. Corton Capital Inc. acquired a new stake in Celcuity in the second quarter worth about $175,000. Trexquant Investment LP raised its position in shares of Celcuity by 131.3% in the 1st quarter. Trexquant Investment LP now owns 26,920 shares of the company’s stock valued at $272,000 after purchasing an additional 15,280 shares during the last quarter. Baker BROS. Advisors LP raised its position in shares of Celcuity by 59.0% in the 1st quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company’s stock valued at $43,046,000 after purchasing an additional 1,579,182 shares during the last quarter. Rhumbline Advisers boosted its stake in Celcuity by 8.9% in the 1st quarter. Rhumbline Advisers now owns 42,194 shares of the company’s stock worth $427,000 after purchasing an additional 3,439 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in Celcuity during the 1st quarter worth approximately $704,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.